594 related articles for article (PubMed ID: 26240221)
21. Racial differences in three major NHL subtypes: descriptive epidemiology.
Li Y; Wang Y; Wang Z; Yi D; Ma S
Cancer Epidemiol; 2015 Feb; 39(1):8-13. PubMed ID: 25560974
[TBL] [Abstract][Full Text] [Related]
22. Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors.
Xavier AC; Armeson KE; Hill EG; Costa LJ
Cancer; 2013 Sep; 119(18):3385-92. PubMed ID: 23797978
[TBL] [Abstract][Full Text] [Related]
23. Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends.
Howlader N; Morton LM; Feuer EJ; Besson C; Engels EA
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):174-9. PubMed ID: 26472423
[TBL] [Abstract][Full Text] [Related]
24. Incidence and epidemiology of non-Hodgkin lymphoma and risk of second malignancy among 22 466 survivors in Israel with 30 years of follow-up.
Tadmor T; Liphshitz I; Silverman B; Polliack A
Hematol Oncol; 2017 Dec; 35(4):599-607. PubMed ID: 27238496
[TBL] [Abstract][Full Text] [Related]
25. Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States.
Shenoy PJ; Malik N; Sinha R; Nooka A; Nastoupil LJ; Smith M; Flowers CR
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):498-506. PubMed ID: 21889433
[TBL] [Abstract][Full Text] [Related]
26. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study.
Spanogle JP; Clarke CA; Aroner S; Swetter SM
J Am Acad Dermatol; 2010 May; 62(5):757-67. PubMed ID: 20223559
[TBL] [Abstract][Full Text] [Related]
27. Evidence for an association between cutaneous malignant melanoma and lymphoid malignancy: a population-based retrospective cohort study in Scotland.
McKenna DB; Stockton D; Brewster DH; Doherty VR
Br J Cancer; 2003 Jan; 88(1):74-8. PubMed ID: 12556962
[TBL] [Abstract][Full Text] [Related]
28. The risk of melanoma in patients with chronic lymphocytic leukemia; a population-based study.
Turk T; Saad AM; Al-Husseini MJ; Gad MM
Curr Probl Cancer; 2020 Apr; 44(2):100511. PubMed ID: 32115255
[TBL] [Abstract][Full Text] [Related]
29. Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer.
Yang GB; Barnholtz-Sloan JS; Chen Y; Bordeaux JS
Arch Dermatol; 2011 Dec; 147(12):1395-402. PubMed ID: 22184761
[TBL] [Abstract][Full Text] [Related]
30. Screening for second malignancies in mycosis fungoides: non-Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and melanoma.
Goyal A; O'Leary D; Goyal K; Rubin N; Janakiram M
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1821-1829. PubMed ID: 34013554
[TBL] [Abstract][Full Text] [Related]
31. Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.
Hester LL; Park SI; Wood WA; Stürmer T; Brookhart MA; Lund JL
Cancer; 2019 Apr; 125(7):1101-1112. PubMed ID: 30548238
[TBL] [Abstract][Full Text] [Related]
32. Second cancers in patients with chronic lymphocytic leukemia.
Travis LB; Curtis RE; Hankey BF; Fraumeni JF
J Natl Cancer Inst; 1992 Sep; 84(18):1422-7. PubMed ID: 1512794
[TBL] [Abstract][Full Text] [Related]
33. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma.
Tward JD; Wendland MM; Shrieve DC; Szabo A; Gaffney DK
Cancer; 2006 Jul; 107(1):108-15. PubMed ID: 16708354
[TBL] [Abstract][Full Text] [Related]
34. Relationship between ambient ultraviolet radiation and non-Hodgkin lymphoma subtypes: a U.S. population-based study of racial and ethnic groups.
Cahoon EK; Pfeiffer RM; Wheeler DC; Arhancet J; Lin SW; Alexander BH; Linet MS; Freedman DM
Int J Cancer; 2015 Mar; 136(5):E432-41. PubMed ID: 25258118
[TBL] [Abstract][Full Text] [Related]
35. Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and skin cancers.
Levi F; Randimbison L; Te VC; La Vecchia C
Br J Cancer; 1996 Dec; 74(11):1847-50. PubMed ID: 8956805
[TBL] [Abstract][Full Text] [Related]
36. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
Rueffer U; Josting A; Franklin J; May M; Sieber M; Breuer K; Engert A; Diehl V;
J Clin Oncol; 2001 Apr; 19(7):2026-32. PubMed ID: 11310450
[TBL] [Abstract][Full Text] [Related]
37. Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia.
Cerhan JR; Vachon CM; Habermann TM; Ansell SM; Witzig TE; Kurtin PJ; Janney CA; Zheng W; Potter JD; Sellers TA; Folsom AR
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1466-71. PubMed ID: 12433728
[TBL] [Abstract][Full Text] [Related]
38. Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012).
Baras N; Dahm S; Haberland J; Janz M; Emrich K; Kraywinkel K; Salama A
Br J Haematol; 2017 Apr; 177(2):226-242. PubMed ID: 28106907
[TBL] [Abstract][Full Text] [Related]
39. Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000-2015.
Schonfeld SJ; Morton LM; Berrington de González A; Curtis RE; Kitahara CM
Cancer Epidemiol; 2020 Feb; 64():101664. PubMed ID: 31884334
[TBL] [Abstract][Full Text] [Related]
40. Increased risk of second primary cancers after a diagnosis of melanoma.
Bradford PT; Freedman DM; Goldstein AM; Tucker MA
Arch Dermatol; 2010 Mar; 146(3):265-72. PubMed ID: 20231496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
